1. Hall C: NT-ProBNP: The mechanism behind the marker. J Card Fail
2005; 11(5 Suppl):S81-83
2. Hall C: Essential biochemistry and physiology of (NT-pro)BNP. Eur
J Heart Fail 2004; 6(3):257-260
3. Kuhn M: Cardiac and intestinal natriuretic peptides: Insights from
genetically modifi ed mice. Peptides 2005; 26(6):1078-1085
4. Martinez-Rumayor A, Richards AM, Burnett JC, Januzzi JL, Jr:
Biology of the natriuretic peptides. Am J Cardiol 2008; 101(3A):3-8
5. Khalifeh N, Haider D, Horl WH: Natriuretic peptides in chronic
kidney disease and during renal replacement therapy: An update. J
Investig Med 2009; 57(1):33-39
6. Maisel AS, Bhalla V, Braunwald E: Cardiac biomarkers: A
contemporary status report. Nat Clin Pract Cardiovasc Med 2006;
3(1):24-34
Axelsson TG, Axelsson J: Elevated NT-pro-BNP in renal patients?
Cilt/Vol: 19, No: 2, 2010, Sayfa/Page: 77-81
80
Türk Nefroloji Diyaliz ve Transplantasyon Dergisi
Turkish Nephrology, Dialysis and Transplantation Journal
7. Wen CP, Cheng TY, Tsai MK, Chang YC, Chan HT, Tsai SP, Chiang
PH, Hsu CC, Sung PK, Hsu YH, Wen SF: All-cause mortality
attributable to chronic kidney disease: a prospective cohort study
based on 462 293 adults in Taiwan. Lancet 2008; 371(9631):2173-
2182
8. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van
Lente F, Levey AS: Prevalence of chronic kidney disease in the
United States. JAMA 2007; 298(17): 2038-2047
9. Cowie MR, Mosterd A, Wood DA, Deckers JW, Poole-Wilson PA,
Sutton GC, Grobbee DE: The epidemiology of heart failure. Eur
Heart J 1997;18(2):208-225
10. Zolty R, Hynes PJ, Vittorio TJ: Severe left ventricular systolic
dysfunction may reverse with renal transplantation: Uremic
cardiomyopathy and cardiorenal syndrome. Am J Transplant 2008;
8(11):2219-2224
11. Guo Q, Barany P, Qureshi AR, Snaedal S, Heimburger O, Stenvinkel
P, Lindholm B, Axelsson J: N-terminal pro-brain natriuretic peptide
independently predicts protein energy wasting and is associated
with all-cause mortality in prevalent HD patients. Am J Nephrol
2009; 29(6):516-523
12. Tagore R, Ling LH, Yang H, Daw HY, Chan YH, Sethi SK:
Natriuretic peptides in chronic kidney disease. Clin J Am Soc
Nephrol 2008; 3(6):1644-1651
13. Madsen LH, Ladefoged S, Corell P, Schou M, Hildebrandt PR, Atar
D: N-terminal pro brain natriuretic peptide predicts mortality in
patients with end-stage renal disease in hemodialysis. Kidney Int
2007; 71(6):548-554
14. Satyan S, Light RP, Agarwal R: Relationships of N-terminal pro-Bnatriuretic
peptide and cardiac troponin T to left ventricular mass
and function and mortality in asymptomatic hemodialysis patients.
Am J Kidney Dis. 2007; 50(6):1009-1019
15. Sommerer C, Beimler J, Schwenger V, Heckele N, Katus HA,
Giannitsis E, Zeier M: Cardiac biomarkers and survival in
haemodialysis patients. Eur J Clin Invest 2007; 37(5):350-356.
16. Pankow K, Wang Y, Gembardt F, Krause E, Sun X, Krause G,
Schultheiss HP, Siems WE, Walther T: Successive action of meprin
A and neprilysin catabolizes B-type natriuretic peptide. Circ Res
2007; 101(9):875-882
17. Palmer SC, Richards AM: Does renal clearance differ between the
B-type natriuretic peptides (BNP versus NT-proBNP)? J Am Coll
Cardiol 2009; 53(10):891-892
18. Manjunath G, Tighiouart H, Coresh J, Macleod B, Salem DN,
Griffi th JL, Levey AS, Sarnak MJ: Level of kidney function as a
risk factor for cardiovascular outcomes in the elderly. Kidney Int
2003; 63(3):1121-1129
19. Freedman BI, Langefeld CD, Lohman KK, Bowden DW, Carr JJ,
Rich SS, Wagenknecht LE: Relationship between albuminuria and
cardiovascular disease in Type 2 diabetes. J Am Soc Nephrol 2005;
16(7):2156-2161
20. Acton RT, Go RC, Roseman JM: Genetics and cardiovascular
disease. Ethn Dis 2004; 14(4):S2-8-16
21. Anavekar NS, Pfeffer MA: Cardiovascular risk in chronic kidney
disease. Kidney Int Suppl 2004 (92):S11-15
22. Shlipak MG, Massie BM: The clinical challenge of cardiorenal
syndrome. Circulation 2004; 110(12):1514-1517
23. Ix JH, Shlipak MG, Liu HH, Schiller NB, Whooley MA: Association
between renal insuffi ciency and inducible ischemia in patients with
coronary artery disease: the heart and soul study. J Am Soc Nephrol
2003; 14(12):3233-3238
24. Christenson RH: What is the value of B-type natriuretic peptide testing
for diagnosis, prognosis or monitoring of critically ill adult patients in
intensive care? Clin Chem Lab Med 2008; 46(11):1524-1532
25. Vickery S, Price CP, John RI, Abbas NA, Webb MC, Kempson ME,
LAmb EJ: B-type natriuretic peptide (BNP) and amino-terminal
proBNP in patients with CKD: Relationship to renal function and left
ventricular hypertrophy. Am J Kidney Dis 2005; 46(4):610-620
26. Hartmann F, Packer M, Coats AJ, Fowler MB, Krum H, Mohacsi
P, Rouleau JL, Tendera M, Castaigne A, Anker SD, Amann-Zalan I,
Hoersch S, Katus HA: Prognostic impact of plasma N-terminal probrain
natriuretic peptide in severe chronic congestive heart failure:
A substudy of the Carvedilol Prospective Randomized Cumulative
Survival (COPERNICUS) trial. Circulation 2004; 110(13):1780-1786
27. Mayer O, Jr., Simon J, Plaskova M, Cifkova R, Trefi l L: N-terminal
pro B-type natriuretic peptide as prognostic marker for mortality
in coronary patients without clinically manifest heart failure. Eur J
Epidemiol 2009
28. Masson S, Latini R, Anand IS, Vago T, Angelici L, Barlera S, Missov
ED, Clerico A, Tognoni G, Cohn JN: Val-HeFT Investigators:
Direct comparison of B-type natriuretic peptide (BNP) and aminoterminal
proBNP in a large population of patients with chronic and
symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT)
data. Clin Chem 2006; 52(8):1528-1538
29. Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R: Nterminal
pro-B-type natriuretic peptide and long-term mortality in
stable coronary heart disease. N Engl J Med 2005; 352(7):666-675
30. Lamba S, Abraham WT: Alterations in adrenergic receptor signaling
in heart failure. Heart Fail Rev 2000; 5(1):7-16
31. Wu AH: Plasma BNP/NT-proBNP assays: what do they target and
what else might they recognize? Heart Fail Clin 2006; 2(3):291-298
32. Green SM, Green JA, Januzzi JL, Jr: Natriuretic peptide testing for
heart failure therapy guidance in the inpatient and outpatient setting.
Am J Ther 2009; 16(2):171-177
33. Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A,
Ordonez-Llanos J, Santalo-Bel M, Pinto YM, Richards M: NTproBNP
testing for diagnosis and short-term prognosis in acute
destabilized heart failure: an international pooled analysis of 1256
patients: the International Collaborative of NT-proBNP Study. Eur
Heart J 2006; 27(3):330-337
34. O’Donoghue M, Chen A, Baggish AL, Anwaruddin S, Krauser DG,
Tung R, Januzzi JL: The effects of ejection fraction on N-terminal
ProBNP and BNP levels in patients with acute CHF: analysis from
the ProBNP Investigation of Dyspnea in the Emergency Department
(PRIDE) study. J Card Fail 2005; 11(5 Suppl):S9-14
Cilt/Vol: 19, No: 2, 2010, Sayfa/Page: 77-81
81
Axelsson TG, Axelsson J: Elevated NT-pro-BNP in renal patients?
Türk Nefroloji Diyaliz ve Transplantasyon Dergisi
Turkish Nephrology, Dialysis and Transplantation Journal
35. Chen AA, Wood MJ, Krauser DG, Baggish AL, Tung R, Anwaruddin
S, Picard MH, Januzzi JL: NT-proBNP levels, echocardiographic
fi ndings, and outcomes in breathless patients: results from the ProBNP
Investigation of Dyspnoea in the Emergency Department (PRIDE)
echocardiographic substudy. Eur Heart J 2006; 27(7):839-845
36. Weber M, Arnold R, Rau M, Elsaesser A, Brandt R, Mitrovic V, Hamm
C: Relation of N-terminal pro B-type natriuretic peptide to progression
of aortic valve disease. Eur Heart J 2005; 26(10):1023-1030
37. Morello A, Lloyd-Jones DM, Chae CU, van Kimmenade RR, Chen
AC, Baggish AL, O’Donoghue M, Lee-Lewandrowski E, Januzzi
JL Jr: Association of atrial fi brillation and amino-terminal pro-brain
natriuretic peptide concentrations in dyspneic subjects with and
without acute heart failure: results from the ProBNP Investigation
of Dyspnea in the Emergency Department (PRIDE) study. Am Heart
J 2007; 153(1):90-97
38. Foote RS, Pearlman JD, Siegel AH, Yeo KT: Detection of exerciseinduced
ischemia by changes in B-type natriuretic peptides. J Am
Coll Cardiol 2004; 44(10):1980-1987
39. Khan IA, Fink J, Nass C, Chen H, Christenson R, deFilippi CR:
N-terminal pro-B-type natriuretic peptide and B-type natriuretic
peptide for identifying coronary artery disease and left ventricular
hypertrophy in ambulatory chronic kidney disease patients. Am J
Cardiol 2006; 97(10):1530-1534
40. Takami Y, Horio T, Iwashima Y, Takiuchi S, Kamide K, Yoshihara
F, Nakamura S, Nakahama H, Inenaga T, Kangawa K, Kawano Y:
Diagnostic and prognostic value of plasma brain natriuretic peptide in
non-dialysis-dependent CRF. Am J Kidney Dis 2004; 44(3):420-428
41. DeFilippi C, van Kimmenade RR, Pinto YM: Amino-terminal pro-
B-type natriuretic peptide testing in renal disease. Am J Cardiol
2008; 101(3A):82-88
42. Zoccali C, Mallamaci F, Benedetto FA, Tripepi G, Parlongo S,
Cataliotti A, Cutrupi S, Giacone G, Bellanuova I, Cottini E, Malatino
LS: Creed Investigators: Cardiac natriuretic peptides are related to
left ventricular mass and function and predict mortality in dialysis
patients. J Am Soc Nephrol 2001; 12(7):1508-1515
43. Wang AY, Lai KN: Use of cardiac biomarkers in end-stage renal
disease. J Am Soc Nephrol 2008; 19(9):1643-1652
44. Clark BA, Elahi D, Shannon RP, Wei JY, Epstein FH: Infl uence of
age and dose on the end-organ responses to atrial natriuretic peptide
in humans. Am J Hypertens 1991; 4(6):500-507
45. Giannessi D, Andreassi MG, Del Ry S, Clerico A, Colombo MG,
Dini N: Possibility of age regulation of the natriuretic peptide Creceptor
in human platelets. J Endocrinol Invest 2001; 24(1):8-16
Thank you for copying data from http://www.arastirmax.com
